Insmed appoints Leo Lee to its Board of Directors

Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, recently announced the appointment of Leo Lee to its Board of Directors. Lee has more than 21 years of experience in the pharmaceutical industry in Japan; most recently at Merck KGaA, a global pharmaceutical company, where he served as President, Japan.

Prior to his role at Merk KGaA, Lee served as President, Japan of Allergan plc, a global pharmaceutical company, from 2011 to 2015. Before that he served as Vice President of Sales at Merck & Co. from 2008 to 2011. From 2003 to 2008, he held various commercial positions at IQVIA (Cegedim Dendrite), a life sciences services company.

Lee has also served in various roles at Accelrys, Inc., a software company serving pharmaceutical and biotech companies, from 1997 to 2003. Currently, Lee serves on the Board of Directors of Regeneus Ltd, a global pharmaceutical company based in Australia. Lee received a B.S. in Molecular Genetics and Microbiology from the University of California, Los Angeles.

Register as Visitor to CPhI China 2018!